Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-01-25

FDA Approved: DAYVIGO — Supplemental Application (Eisai Inc.)

View source ↗

Summary

FDA approves a supplemental application for DAYVIGO (lemorexant) from Eisai Inc., incorporating labeling changes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dayvigo (lemborexant)

Snippet

SUPPL AP for DAYVIGO (LEMBOREXANT)